Buck Christopher B, Pastrana Diana V, Lowy Douglas R, Schiller John T
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892-4263, USA.
J Virol. 2004 Jan;78(2):751-7. doi: 10.1128/jvi.78.2.751-757.2004.
Although the papillomavirus structural proteins, L1 and L2, can spontaneously coassemble to form virus-like particles, currently available methods for production of L1/L2 particles capable of transducing reporter plasmids into mammalian cells are technically demanding and relatively low-yield. In this report, we describe a simple 293 cell transfection method for efficient intracellular production of papillomaviral-based gene transfer vectors carrying reporter plasmids. Using bovine papillomavirus type 1 (BPV1) and human papillomavirus type 16 as model papillomaviruses, we have developed a system for producing papillomaviral vector stocks with titers of several billion transducing units per milliliter. Production of these vectors requires both L1 and L2, and transduction can be prevented by papillomavirus-neutralizing antibodies. The stocks can be purified by an iodixanol (OptiPrep) gradient centrifugation procedure that is substantially more effective than standard cesium chloride gradient purification. Although earlier data had suggested a potential role for the viral early protein E2, we found that E2 protein expression did not enhance the intracellular production of BPV1 vectors. It was also possible to encapsidate reporter plasmids devoid of BPV1 DNA sequences. BPV1 vector production efficiency was significantly influenced by the size of the target plasmid being packaged. Use of 6-kb target plasmids resulted in BPV1 vector yields that were higher than those with target plasmids closer to the native 7.9-kb size of papillomavirus genomes. The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism.
尽管乳头瘤病毒结构蛋白L1和L2能够自发共同组装形成病毒样颗粒,但目前用于生产能够将报告质粒转导至哺乳动物细胞的L1/L2颗粒的方法技术要求高且产量相对较低。在本报告中,我们描述了一种简单的293细胞转染方法,用于在细胞内高效生产携带报告质粒的乳头瘤病毒基因转移载体。以1型牛乳头瘤病毒(BPV1)和16型人乳头瘤病毒作为乳头瘤病毒模型,我们开发了一种生产乳头瘤病毒载体储备液的系统,其滴度可达每毫升数十亿转导单位。这些载体的生产需要L1和L2两者,并且转导可被乳头瘤病毒中和抗体阻止。该储备液可通过碘克沙醇(OptiPrep)梯度离心法纯化,该方法比标准氯化铯梯度纯化法有效得多。尽管早期数据表明病毒早期蛋白E2可能发挥作用,但我们发现E2蛋白表达并未增强BPV1载体在细胞内的产生。也有可能将不含BPV1 DNA序列的报告质粒包装起来。BPV1载体的生产效率受被包装的目标质粒大小的显著影响。使用6 kb的目标质粒所产生的BPV1载体产量高于使用更接近乳头瘤病毒基因组天然7.9 kb大小的目标质粒时的产量。结果表明,乳头瘤病毒结构蛋白围绕异源报告质粒在细胞内的组装出人意料地随意,并且可能主要由大小区分机制驱动。